IDEAYA Biosciences reported collaboration revenue growth in Q4 2025, driven by its Servier license agreement, while significantly narrowing its net loss year-over-year. The company ended the quarter with over $1.04 billion in cash, cash equivalents, and marketable securities, supporting operations into 2030.

IDEAYA Biosciences generated substantial collaboration revenue in Q3 2025 from the Servier darovasertib license, leading to a notable net income compared to prior losses and bolstering its cash position to support operations into 2030.

IDEAYA Biosciences reported a net loss of $72.2 million for Q1 2025, with no collaboration revenue. The company maintained a strong cash position of approximately $1.05 billion, extending its cash runway into 2029. Significant progress was made in the darovasertib program, including achieving Breakthrough Therapy Designation and advancing patient enrollment in registrational trials.

IDEAYA Biosciences reported a net loss of $130.3 million for the three months ended December 31, 2024. As of December 31, 2024, IDEAYA had cash, cash equivalents and marketable securities of approximately $1.1 billion, anticipated to fund operations into at least 2028.

IDEAYA Biosciences reported its Q3 2024 financial results, highlighting a transformational quarter with significant clinical and corporate developments, including a successful FDA Type C meeting, a late-breaker oral presentation at ENA 2024, and the receipt of IND clearance for Werner Helicase inhibitor IDE275.

IDEAYA Biosciences reported $952.7 million in cash, cash equivalents and marketable securities as of June 30, 2024. Significant progress was made advancing four potential first-in-class precision medicine oncology clinical programs. Preliminary clinical proof of concept data was presented for IDE397 monotherapy in MTAP-deletion urothelial and lung cancer.

IDEAYA Biosciences reported a net loss of $39.6 million for the first quarter ended March 31, 2024. As of March 31, 2024, IDEAYA had cash, cash equivalents and marketable securities totaling $941.4 million.

IDEAYA Biosciences reported a net loss of $34.0 million for the fourth quarter of 2023, compared to a net loss of $24.2 million for the same period in 2022. The company's cash, cash equivalents, and marketable securities totaled $632.6 million as of December 31, 2023, which, supplemented by net proceeds from January 2024 ATM offerings, is expected to fund operations into 2028.

IDEAYA Biosciences reported a strong balance sheet with $511.1 million in cash, cash equivalents, and marketable securities as of September 30, 2023, supplemented by $134.7 million in estimated net proceeds from a subsequent follow-on financing and $10.0 million receivable from GSK milestones. The company is advancing its clinical pipeline with multiple ongoing trials for darovasertib, IDE397, and IDE161, and has achieved IND clearance for GSK101, triggering a $7.0 million milestone payment from GSK.